Cantex Pharmaceuticals, Inc. (Cantex), a clinical stage biopharmaceutical company developing proprietary compounds to enhance the efficacy and safety of the treatment of various cancers and related blood disorders, announced that the United States Patent and Trademark Office (USPTO) has issued US Patent number 9,271,999 to Cantex entitled, “Treatment of Myelosuppression”.

The patent, which will be in force until March 2033, provides proprietary protection for the use of the company’s lead product candidate, known as CX 01, in the treatment of thrombocytopenia and neutropenia. The patent also covers use of related compounds in the treatment of thrombocytopenia and neutropenia. This new patent further fortifies the company’s already robust patent portfolio, which includes 11 previously granted patents, including U.S. Patent 8,734,804, which provides proprietary protection until March 2033 for some uses of CX-01 in cancer treatment, as well as numerous pending patent applications.

Stephen G. Marcus, M.D., president and CEO of Cantex, commented, "This new patent for CX-01 is a significant addition to our intellectual property estate and provides proprietary protection for the use of CX-01 in thrombocytopenia, a condition of low platelets, and neutropenia, a condition in which there are inadequate infection-fighting white blood cells called neutrophils. We are exploring the efficacy and safety of CX-01 in a range of cancers and other illnesses in which thrombocytopenia and neutropenia may be a source of life-threatening complications."